HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Essen, M. Articles by Kwekkeboom, D. J. Search for Related Content PubMed PubMed Citation Articles by van Essen, M. Articles by Kwekkeboom, D. J.

Effects of Therapy with [¹⁷⁷Lu-DOTA⁰, Tyr³]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma

¹ Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; ² Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; and ³ Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands

Correspondence: For correspondence or reprints contact: Martijn van Essen, MD, Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. E-mail: m.vanessen{at}erasmusmc.nl

Therapy using the radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate (¹⁷⁷Lu-octreotate) (DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) has been used primarily in gastroenteropancreatic neuroendocrine tumors. Here we present the effects of this therapy in a small number of patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas (SCLCs), and melanomas. Methods: Twelve patients with paraganglioma, 5 with meningioma, 3 with SCLC, and 2 with eye melanoma were treated. Three meningiomas were very large and exophytic and all standard treatments had failed. Patients with melanoma had rapidly progressive disease (PD). The intended cumulative dose of ¹⁷⁷Lu-octreotate was 22.2–29.6 GBq. Effects of the treatment on tumor size were evaluated using the Southwest Oncology Group criteria. Results: Two of 4 patients with progressive paraganglioma had tumor regression and 1 had stable disease (SD). Of 5 patients with stable paraganglioma, 2 had SD, 2 had PD, and in 1 patient treatment outcome could not be determined. Paraganglioma was stable in 3 patients in whom the disease status at the beginning of therapy was unknown. One of 4 patients with progressive meningioma had SD and 3 patients had PD. One patient with stable meningioma at the beginning of therapy had SD. All patients with SCLC or melanoma died within 5 mo after starting therapy because of tumor progression. Although not statistically significant, a positive trend was found between high uptake on pretherapy somatostatin receptor scintigraphy and treatment outcome. Conclusion: ¹⁷⁷Lu-Octreotate can be effective in patients with paraganglioma and meningioma. Response rates are lower than those in patients with gastroenteropancreatic neuroendocrine tumors. Most meningiomas were very large. Further studies are needed to confirm the treatment outcome because of the limited number of patients. ¹⁷⁷Lu-Octreotate did not have antitumor effects in patients with small lung carcinoma and melanoma.

Key Words: ¹⁷⁷Lu-octreotate • paraganglioma • meningioma • small cell lung carcinoma • melanoma

Related articles in JNM:

This Month in JNM

JNM 2006 47: 9a-10a. [Full Text]  

This article has been cited by other articles:

				K. P. Koopmans, P. L. Jager, I. P. Kema, M. N. Kerstens, F. Albers, and R. P.F. Dullaart 111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas J. Nucl. Med., August 1, 2008; 49(8): 1232 - 1237. [Abstract] [Full Text] [PDF]

				B. Havekes, E. P. M. Corssmit, J. C. Jansen, A. G. L. van der Mey, A. H. J. T. Vriends, and J. A. Romijn Malignant Paragangliomas Associated with Mutations in the Succinate Dehydrogenase D Gene J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1245 - 1248. [Abstract] [Full Text] [PDF]